PE20221731A1 - NUEVO USO DE FORMULACION INMUNOGENICA BCG QUE EXPRESA UNA PROTEINA DE VIRUS RESPIRATORIO SINCICIAL CONTRA hMPV - Google Patents

NUEVO USO DE FORMULACION INMUNOGENICA BCG QUE EXPRESA UNA PROTEINA DE VIRUS RESPIRATORIO SINCICIAL CONTRA hMPV

Info

Publication number
PE20221731A1
PE20221731A1 PE2022001328A PE2022001328A PE20221731A1 PE 20221731 A1 PE20221731 A1 PE 20221731A1 PE 2022001328 A PE2022001328 A PE 2022001328A PE 2022001328 A PE2022001328 A PE 2022001328A PE 20221731 A1 PE20221731 A1 PE 20221731A1
Authority
PE
Peru
Prior art keywords
immunogenic
expresses
protein
respiratory syncitial
syncitial virus
Prior art date
Application number
PE2022001328A
Other languages
English (en)
Inventor
Parra Alexis Mikes Kalergis
Ramiirez Susana Marcela Bueno
Munoz Pablo Alberto Gonzales
Original Assignee
Univ Pontificia Catolica Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pontificia Catolica Chile filed Critical Univ Pontificia Catolica Chile
Publication of PE20221731A1 publication Critical patent/PE20221731A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE AL USO DE UNA FORMULACION INMUNOGENICA QUE CONTIENE LA CEPA BACILO DE CALMETTE Y GUERIN (BCG), QUE EXPRESA UNA PROTEINA O FRAGMENTO INMUNOGENICO DEL VIRUS RESPIRATORIO SINCICIAL (VRS) EN UNA SOLUCION TAMPON SALINA FARMACEUTICAMENTE ACEPTABLE DONDE LA PROTEINA O FRAGMENTO INMUNOGENICO DE VRS CORRESPONDE A LA PROTEINA DE LA NUCLEOCAPSIDE (PROTEINA N) DE VRS; EN DONDE LA FORMULACION PUEDE SER UTILIZADA EN CONJUNTO CON OTRAS FORMULACIONES INMUNOGENICAS, QUE EXPRESEN PROTEINAS O FRAGMENTOS INMUNOGENICOS DIFERENTES DE N DE VRS. DICHA FORMULACION INMUNOGENICA SIRVE PARA PREPARAR UNA VACUNA UTIL PARA PREVENIR, TRATAR, O ATENUAR INFECCIONES DE METAPNEUMOVIRUS HUMANO.
PE2022001328A 2019-12-26 2020-12-24 NUEVO USO DE FORMULACION INMUNOGENICA BCG QUE EXPRESA UNA PROTEINA DE VIRUS RESPIRATORIO SINCICIAL CONTRA hMPV PE20221731A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2019003847A CL2019003847A1 (es) 2019-12-26 2019-12-26 Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv
PCT/CL2020/050193 WO2021127797A1 (es) 2019-12-26 2020-12-24 NUEVO USO DE FORMULACIÓN INMUNOGÉNICA BCG QUE EXPRESA UNA PROTEÍNA DE VIRUS RESPIRATORIO SINCICIAL CONTRA hMPV

Publications (1)

Publication Number Publication Date
PE20221731A1 true PE20221731A1 (es) 2022-11-07

Family

ID=76573373

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001328A PE20221731A1 (es) 2019-12-26 2020-12-24 NUEVO USO DE FORMULACION INMUNOGENICA BCG QUE EXPRESA UNA PROTEINA DE VIRUS RESPIRATORIO SINCICIAL CONTRA hMPV

Country Status (9)

Country Link
US (1) US20230055706A1 (es)
EP (1) EP4082566A4 (es)
JP (1) JP2023508505A (es)
CN (1) CN115023238A (es)
AR (1) AR120887A1 (es)
CL (1) CL2019003847A1 (es)
MX (1) MX2022008036A (es)
PE (1) PE20221731A1 (es)
WO (1) WO2021127797A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2020002568A1 (es) * 2020-10-05 2022-08-05 Univ Pontificia Catolica Chile Formulación inmunogénica que contiene una cepa bcg modificada que expresa una proteína de andesvirus (andv) útil para prevenir y tratar infecciones por virus hanta-andv

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002710A1 (es) * 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
CL2013002829A1 (es) * 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
CN108348593B (zh) * 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗

Also Published As

Publication number Publication date
CN115023238A (zh) 2022-09-06
MX2022008036A (es) 2022-08-22
US20230055706A1 (en) 2023-02-23
JP2023508505A (ja) 2023-03-02
EP4082566A4 (en) 2024-03-13
EP4082566A1 (en) 2022-11-02
WO2021127797A1 (es) 2021-07-01
AR120887A1 (es) 2022-03-30
CL2019003847A1 (es) 2021-08-06

Similar Documents

Publication Publication Date Title
DOP2023000187A (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
WO2016070166A3 (en) Messenger una molecules and uses thereof
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
MX2018002732A (es) Composicion y dispositivo medico que comprenden acido acetilsalicilico para el tratamiento de infecciones cutaneas por virus de papiloma humano.
CL2022000774A1 (es) Vacunas para vhb y métodos de tratamiento de vhb
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2024004936A (es) Variantes de capsides de aav y sus usos.
MX2023003199A (es) Vacuna contra la enfermedad por coronavirus de 2019 (covid-19) basada en el virus de la parainfluenza 5 (piv5).
PE20090653A1 (es) Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc
MX2020008454A (es) Composicion inmunogenica que comprende antigenos estafilococicos.
TW201612190A (en) Flavivirus virus like particle
MX2023004933A (es) Proteinas de fusion de ace2 y usos de las mismas.
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
WO2015095167A3 (en) Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
PE20221731A1 (es) NUEVO USO DE FORMULACION INMUNOGENICA BCG QUE EXPRESA UNA PROTEINA DE VIRUS RESPIRATORIO SINCICIAL CONTRA hMPV
ZA202003070B (en) Lassa vaccine
MX2020008415A (es) Metodos y composiciones que actuan de forma selectiva sobre linfocitos treg.
BR112023002926A2 (pt) Agentes terapêuticos inaláveis
CL2013002829A1 (es) Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
WO2019087133A8 (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists
WO2019059817A9 (en) VACCINE BASED ON FUSION PROTEIN AND PLASMIDIC DNA
MX2024002472A (es) Cocristales.
AR087811A1 (es) Vacuna contra el staphylococcus aureus